Barely Significant

Excerpts

27,100 sentences · 1 filter applied

This model compares the first two agents with randomized controlled trial data showing potential mortality benefit in moderate-severe COVID-19 infections, with remdesivir showing a statistical trend to survival in the preliminary report with a larger effect in patients with moderate infections and dexamethasone demonstrating a statistically significant benefit in both moderate and severe infections.